IRIDEX Corporation — Q1 2014 Form 10-Q
Reporting period: Three months ended March 29, 2014; comparative period ended March 30, 2013. IRIDEX develops, manufactures and markets ophthalmic laser systems, delivery devices, consumables and related services. It reports one operating segment, ophthalmology. Financial statements are unaudited.
Financial performance
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Revenue | $10.329 million | $8.939 million | Up 15.5% |
| Gross profit / margin | $5.055 million / 48.9% | $4.231 million / 47.3% | Profit up 19.5%; margin up 1.6 points |
| Operating income / margin | $0.597 million / 5.7% | $0.897 million / 10.0% | Down 33.4% |
| Net income / diluted EPS | $0.487 million / $0.05 | $0.874 million / $0.09 | Net income down 44.3% |
| Operating cash flow | $0.645 million | $(0.406) million | Improved |
Cash and cash equivalents were $13.969 million at quarter-end, compared with $13.444 million at December 28, 2013. Working capital was $25.2 million, versus $24.6 million. Total liabilities were $6.413 million; the company reported no fixed- or variable-rate debt outstanding. Q1 investing cash outflow was $0.202 million, including $0.108 million for property and equipment and $0.094 million of earn-out payments. Financing cash flow was $0.082 million, including $0.329 million from option exercises and $0.247 million of stock repurchases.
Changes and drivers
- System revenue rose 24.9% to $5.502 million: domestic systems increased 17.9% and international systems increased 31.4%. Recurring revenue rose 6.3% to $4.827 million. OEM revenue fell to zero after Bausch & Lomb discontinued the product.
- Management attributed revenue growth to IQ laser and TxCell sales, the Peregrine product and sales-force arrangements, and higher royalties from Alcon. International sales were $5.624 million, or 54.4% of revenue.
- Gross margin improved through pricing discipline, lower material costs and overhead efficiencies, partly offset by a higher share of international distribution sales.
- Operating expenses increased 33.7% to $4.458 million. R&D spending rose with IQ platform cost-reduction and other product-development work; G&A included approximately $0.1 million of severance and higher stock compensation.
- Q1 2013 included a one-time $0.473 million insurance-carrier demutualization benefit. Q1 2014 also included a $0.099 million expense from remeasuring the acquisition earn-out liability, versus $0.019 million in Q1 2013. These items affected the year-over-year operating and other-expense comparisons.
Liquidity, outlook and risks
Management said cash and expected operating cash flows should be sufficient to fund operations for the next 12 months. No quantitative revenue or earnings guidance was provided. Contractual obligations totaled $4.272 million, comprising $0.996 million of operating leases and $3.276 million of purchase commitments; $1.706 million was due within one year. The company reported no material off-balance-sheet arrangements.
Management cautioned that results may fluctuate with product and geographic mix, seasonality, shipment timing, demand, pricing, production costs and market acceptance. Key risks include competition and alternative treatments, reimbursement uncertainty, reliance on international distributors and limited-source suppliers, product development and regulatory requirements, and currency-related competitiveness. Most transactions are in U.S. dollars; the company does not currently hedge currency risk. Ordinary-course legal matters were not expected by management to have a material adverse effect. Disclosure controls were concluded effective at the reasonable-assurance level, with no material change in internal control reported.
Important facts for investors to verify
- Whether revenue growth, particularly international system sales and recurring revenue, continues and translates into sustained operating profitability.
- How expense growth, product/channel mix and the absence of the prior-year demutualization benefit affect future margins and earnings.
- Cash conversion and working-capital needs, including inventory and receivables; one customer represented more than 10% of quarter-end receivables, though no customer exceeded 10% of quarterly revenue.
- Execution of product-development plans, market acceptance, regulatory compliance, supplier continuity and distributor relationships.
- Stock repurchases and dilution: the company repurchased 39,813 shares at an average $8.69 during the quarter and retained authorization for approximately $2.228 million of purchases.